logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Braf Targets In Melanoma Biological Mechanisms Resistance And Drug Discovery 1st Edition Ryan J Sullivan Eds

  • SKU: BELL-4972162
Braf Targets In Melanoma Biological Mechanisms Resistance And Drug Discovery 1st Edition Ryan J Sullivan Eds
$ 31.00 $ 45.00 (-31%)

0.0

0 reviews

Braf Targets In Melanoma Biological Mechanisms Resistance And Drug Discovery 1st Edition Ryan J Sullivan Eds instant download after payment.

Publisher: Springer-Verlag New York
File Extension: PDF
File size: 4.64 MB
Pages: 204
Author: Ryan J. Sullivan (eds.)
ISBN: 9781493921423, 1493921428
Language: English
Year: 2015
Edition: 1

Product desciption

Braf Targets In Melanoma Biological Mechanisms Resistance And Drug Discovery 1st Edition Ryan J Sullivan Eds by Ryan J. Sullivan (eds.) 9781493921423, 1493921428 instant download after payment.

​This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that this drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma.

Related Products